ATORXS logo

Alligator Bioscience BATS-CHIXE:ATORXS Stock Report

Last Price

SEK 0.80

Market Cap

SEK 384.7m

7D

0%

1Y

n/a

Updated

19 Jun, 2023

Data

Company Financials +

Alligator Bioscience AB (publ)

BATS-CHIXE:ATORXS Stock Report

Market Cap: SEK 384.7m

ATORXS Stock Overview

A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. More details

ATORXS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Alligator Bioscience AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alligator Bioscience
Historical stock prices
Current Share PriceSEK 0.80
52 Week HighSEK 0.80
52 Week LowSEK 0.80
Beta1.15
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-91.53%
5 Year Change-97.66%
Change since IPO-97.75%

Recent News & Updates

Recent updates

Shareholder Returns

ATORXSGB BiotechsGB Market
7D0%-0.2%0.5%
1Yn/a-25.8%2.7%

Return vs Industry: Insufficient data to determine how ATORXS performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how ATORXS performed against the UK Market.

Price Volatility

Is ATORXS's price volatile compared to industry and market?
ATORXS volatility
ATORXS Average Weekly Movementn/a
Biotechs Industry Average Movement7.0%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: ATORXS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ATORXS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200058Søren Bregenholtwww.alligatorbioscience.se

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, an agonistic antibody that targets CD40, which is in phase 2 clinical trail for the treatment solid metastatic tumors, initially pancreatic cancer; and ATOR-4066, a bispecific antibody tumor-specific immune effect, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ATOR-1017, a 4-1BB for solid metastatic tumors which is in Phase 1 clinical trial; and ALG

Alligator Bioscience AB (publ) Fundamentals Summary

How do Alligator Bioscience's earnings and revenue compare to its market cap?
ATORXS fundamental statistics
Market capSEK 384.75m
Earnings (TTM)-SEK 212.87m
Revenue (TTM)SEK 40.45m

9.5x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATORXS income statement (TTM)
RevenueSEK 40.45m
Cost of RevenueSEK 169.05m
Gross Profit-SEK 128.59m
Other ExpensesSEK 84.28m
Earnings-SEK 212.87m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Jul 13, 2023

Earnings per share (EPS)-0.34
Gross Margin-317.87%
Net Profit Margin-526.20%
Debt/Equity Ratio0%

How did ATORXS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/19 15:22
End of Day Share Price 2023/03/22 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alligator Bioscience AB (publ) is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ingrid GafanhãoKempen & Co. NV
Carl RamaniusRedeye